Sionna Therapeutics, Inc. (SION) AI Stock Analysis

• Market Cap: $1.51B
• Dividend Yield: N/A
• Average Volume (3M): 254.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 44,628,788
• 10 Day Avg. Volume: 146,250
• 30 Day Avg. Volume: 254,913
• PEG Ratio: -0.64
• Price to Book (P/B): 5.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.66
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -5.96K
• Enterprise Value/Ebitda: -19.56
• 1Y Price Target: $51.17
• Price Target Upside: 50.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $33.00 ▼(-2.71% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held down by pre-revenue operations with widening losses and significant, persistent cash burn. A strengthened 2025 balance sheet with low debt provides some stability, but technicals remain weak with the stock below key short- and mid-term moving averages and negative MACD. Valuation support is limited because the negative P/E is driven by losses and no dividend yield is available.

Positive Factors

Strong balance sheet

The balance sheet materially strengthened in 2025: equity flipped positive to $306.8M while total debt remained small (~$8.68M, debt/equity ~0.03). This durable capital base reduces solvency risk, supports multi-year R&D spending, and improves financial flexibility during clinical development.

Multi-year cash runway

A cash position of ~$310M and management guidance that cash should fund operations into 2028 provides a multi-year runway. That reduces near-term dilution risk and allows the company to progress multiple clinical programs and planned 2026 readouts without immediate capital raises.

Advancing CF pipeline

Delivering positive Phase 1 data for two first-in-class NBD1 stabilizers and advancing both candidates increases the company's probability of technical success. Multiple active programs create 'shots on goal,' diversifying clinical risk and supporting longer-term value creation if later-stage results confirm activity.

Negative Factors

Pre-revenue model

Sionna is a development-stage biotech with no product revenue, so value is driven entirely by R&D outcomes. This structural lack of operating revenue means sustained losses and reliance on financing until commercialization, making long-term execution and clinical success critical to viability.

Heavy, rising cash burn

Operating cash flow and free cash flow were deeply negative and worsened to roughly -$66M in 2025, indicating rising cash needs as programs advance. Persistent cash burn means the company will eventually need external funding if pipelines extend, creating dilution or financing execution risk over the medium term.

Negative returns despite equity

Although equity turned positive, returns remain negative (ROE ~-24.5% in 2025), showing that capital raised has yet to produce profitable outcomes. This highlights structural profitability risk: even with a stronger capital base, the company must translate R&D spend into successful clinical milestones to justify invested capital.

Sionna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

How the Company Makes Money

Sionna Therapeutics, Inc. Financial Statement Overview

Summary

Income statement and cash flow are weak: the company is pre-revenue with widening losses (EBIT down to -$88.98M in 2025) and rising cash burn (operating cash flow -$66.30M in 2025). The key offset is a stronger balance sheet in 2025 with positive equity ($306.8M) and low leverage (debt-to-equity ~0.03), improving financial resilience despite ongoing negative returns.

Income Statement

The company is pre-revenue (revenue is 0 across the period), so operating losses are the key story. Losses have widened over time, with EBIT declining from -$41.4M (2022) to -$88.98M (2025), and net income falling from -$40.24M to -$75.27M. This trajectory indicates increasing spend without an offsetting revenue base yet, which is typical for development-stage biotech but still a clear profitability headwind.

Balance Sheet

Leverage is low, with total debt at $8.68M in 2025 and a low debt-to-equity of ~0.03, which reduces financial risk. The balance sheet also improved materially in 2025 as stockholders’ equity turned positive ($306.8M) versus negative equity in 2022–2024, suggesting a significant financing event and a stronger capital base. The main weakness is that returns are negative when equity is positive (2025 return on equity is about -24.5%), reflecting ongoing losses despite the strengthened balance sheet.

Cash Flow

Cash burn remains heavy and persistent: operating cash flow was negative each year and worsened to -$66.30M in 2025 (from -$36.07M in 2022), with free cash flow similarly negative at -$66.67M in 2025. A positive point is that free cash flow broadly tracks net losses (free cash flow to net income near ~1x), implying reported losses are largely reflected in cash usage rather than being driven by large non-cash accounting items. Still, the overall trend shows rising cash needs and ongoing reliance on external funding until revenue materializes.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-247.00K	0.00	-668.00K	0.00	0.00
EBITDA	-75.29M	-88.98M	-69.89M	-49.75M	-41.25M
Net Income	-70.68M	-75.27M	-61.69M	-47.26M	-40.24M
Balance Sheet
Total Assets	339.27M	325.95M	185.75M	51.95M	87.37M
Cash, Cash Equivalents and Short-Term Investments	248.33M	235.88M	147.54M	38.52M	82.61M
Total Debt	8.97M	8.68M	9.75M	10.48M	0.00
Total Liabilities	17.60M	19.12M	349.46M	166.83M	157.29M
Stockholders Equity	321.67M	306.83M	-163.71M	-114.88M	-69.92M
Cash Flow
Free Cash Flow	-61.65M	-66.67M	-52.81M	-44.81M	-37.94M
Operating Cash Flow	-61.45M	-66.30M	-52.79M	-43.70M	-36.07M
Investing Cash Flow	-126.11M	-118.75M	-126.91M	27.35M	-29.26M
Financing Cash Flow	202.64M	205.71M	178.97M	31.00K	110.86M

Sionna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	64 Neutral	$1.47B	-2.95	-45.73%	―	-78.55%	7.74%
STOK	61 Neutral	$2.10B	55.60	15.02%	―	1128.17%	―
IMTX	56 Neutral	$1.34B	―	-29.00%	―	-27.61%	-69.49%
AMLX	55 Neutral	$1.68B	―	-56.52%	―	-100.34%	52.85%
TNGX	53 Neutral	$1.55B	-12.58	-51.65%	―	53.28%	21.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SION	45 Neutral	$1.51B	-21.22	-28.07%	―	―	―